Deborah Hasin, PhD

  • Professor of Epidemiology (in Psychiatry) at CUMC
646-774-7909

On the web

Profile Headshot

Profile Navigation

Overview

Dr. Deborah Hasin is a Professor of Clinical Epidemiology at Columbia University in the College of Physicians and Surgeons, Department of Psychiatry, with a joint appointment in the Mailman School of Public Health, Department of Epidemiology. Her current research focuses on drug use, drug use disorders, and psychiatric comorbidity in the general population and in large patient groups, including veterans. Dr. Hasin received her PhD in epidemiology from Columbia University in 1986. She directs the Substance Dependence Research Group in the Department of Translational Epidemiology and is the founding director of the NIDA-funded Substance Abuse Epidemiology Training Program (SAETP) at Columbia University.

Dr. Hasin’s full CV is here.

Academic Appointments

  • Professor of Epidemiology (in Psychiatry) at CUMC

Gender

  • Female

Credentials & Experience

Education & Training

  • BA, 1972 University of California
  • MS, 1980 Columbia University
  • PhD, 1986 Columbia University

Research

Dr. Hasin’s current research focuses on large-scale social influences on time trends in cannabis use and cannabis-related harms, and on concepts and measures of addiction and recovery/remission across psychoactive substances. Her studies on drugs and alcohol have been continuously funded by the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism since 1990.

Dr. Hasin has been actively involved in many professional organizations and activities. She was the President of the College on Problems of Drug Dependence in 2023-2024, and was the text editor for the Substance Use Disorder sections of DSM-5-TR. In the past, she has been President of the American Psychopathological Association and has served as a member of many other national and international advising and consultative groups. Dr. Hasin has over 550 publications, including papers on time trends and state-level influences on cannabis use, cannabis use disorder, binge drinking, and alcohol use disorders and in DSM-5 definitions of substance use disorders in the general population and clinical samples. Dr. Hasin’s diagnostic research interview, the PRISM, is in use in numerous studies of the relationship of substance and psychiatric disorders in the U.S. and internationally.

Research interests include:

  1. Impact of Medical and Recreational Marijuana Laws on Cannabis, Opioids and Psychiatric Medications among patients in the US Veterans Administration, 2005-present
  2. Prospective benefits of non-abstinent reductions in heavy drinking levels in U.S. adults
  3. Measurement and risk for addiction to prescription opioid medication among chronic pain patients
  4. Leveraging social media to develop a standardized measure of cannabis use
  5. Reliability and validity of DSM-5 changes in SUD diagnostic criteria

Selected Publications

Cannabis Use Disorder

  1. Hasin DS, Shmulewitz D, CerdáM, Keyes KM, Olfson M, Sarvet AL, Wall MM. US adults with pain, an increasingly vulnerable group for non-medical cannabis use and cannabis use disorder: 2001-2002 and 2012-2013.Am J Psychiatry. 2020 Jan 22PMID: 31964162
  2. Hasin DS, Saxon AJ, Malte C, Olfson M, Keyes KM, Gradus JL, Cerda M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, Mannes Z, Wall MM. Trends in Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration, 2005-2019. Am J Psychiatry. 2022;179(10):748-757. PMCID: PMC9529770
  3. Mannes ZL, Malte CA, Olfson M, Wall MM, Keyes KM, Martins SS, Cerda M, Gradus JL, Saxon AJ, Keyhani S, Maynard C, Livne O, Fink DS, Gutkind S, Hasin DS. Increasing risk of cannabis use disorder among U.S. veterans with chronic pain: 2005-2019. Pain. 2023. PMID: 37159542.
  4. Livne O, Malte CA, Olfson M, Wall MM, Keyes KM, Maynard C, Gradus JL, Saxon AJ, Martins SS, Keyhani S, McDowell Y, Fink DS, Mannes ZL, Gutkind S, Hasin DS. Trends in Prevalence of Cannabis Use Disorder Among U.S. Veterans With and Without Psychiatric Disorders Between 2005 and 2019. Am J Psychiatry. 2024 Feb 1;181(2):144-152
  5. Fink DS, Malte C, Cerda M, Mannes ZL, Livne O, Martins SS, Keyhani S, Olfson M, McDowell Y, Gradus JL, Wall MM, Sherman S, Maynard CC, Saxon AJ, Hasin DS. Trends in Cannabis-positive Urine Toxicology Test Results: US Veterans Health Administration Emergency Department Patients, 2008 to 2019. J Addict Med. 2023. PMID: 37418654.
  6. Hasin DS, Wall MM, Choi CJ, Alschuler DM, Malte C, Olfson M, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, Mannes Z, Sherman S, Saxon AJ. State Cannabis Legalization and Increases in Cannabis Use Disorder in the U.S. Veterans Health Administration, 2005 to 2019. JAMA Psychiatry. 2023. PMCID: PMC9979011
  7. Hasin DS, Wall MM, Alschuler DM, Mannes Z, Malte C, Olfson M, Keyes KM, Gradus JL, Cerdá M, Maynard CC, Keyhani S, Martins SS, Fink DS, Livne O, McDowell Y, Sherman S, Saxon AJ. Chronic pain, cannabis legalization and cannabis use disorder in the US Veterans Health Administration, 2005 to 2019, a repeated, cross-sectional study. Lancet Psychiatry. In press, 2023
  8. Hasin DS, Sarvet AL, Cerdá M, Keyes KM, Stohl M, Galea S, Wall MM. U.S. Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws: 1991-1992 to 2012-2013. JAMA Psychiatry. 2017 Jun 1;74(6):579-588. PMCID: PMC5539836

Diagnosis of Substance Use Disorders

  1. Hasin, DS, Stohl, M. Higher prevalence estimates of substance use disorders using DSM-5 vs. DSM-IV criteria among US nonelderly adults with substance use: The role of DSM-IV diagnostic orphans. Am J Psychiatry. 2024. In press.
  2. Hasin DS, O’Brien CP, Auriacombe M, Borges G, Bucholz K, Budney A, Compton WM, Crowley T, Ling W, Petry NM, Schuckit M, Grant BF. (2013). DSM-5 Criteria for Substance Disorders: Recommendations and Rationale. Am J Psychiatry. 170(8), 834–851. PMCID: PMC3767415.
  3. Hasin DS, Shmulewitz D, Stohl M, Greenstein E, Aharonovich E, Petronis KR, Von Korff M, Datta S, Sonty N, Ross S, Inturrisi C, Weinberger ML, Scodes J, Wall MM. Diagnosing prescription opioid use disorder among patients using prescribed opioids for chronic pain. Am J Psychiatry. 2022 Oct;179(10):715-725. PMID: 35702830
  4. Hasin D, Shmulewitz D, Stohl M, Greenstein E, Roncone S, Aharonovich E, Wall M. Test-retest reliability of DSM-5 substance disorder measures as assessed with the PRISM-5, a clinician-administered diagnostic interview. Drug Alcohol Depend. 2020 Nov 1;216:108294. doi: 10.1016/j.drugalcdep.2020.108294. Epub 2020 Sep 15.PMID: 33007702
  5. Fink DS, Shmulewitz D, Mannes ZL, Stohl M, Livne O, Wall M, Hasin DS Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use. J Psychiatr Res. 2022 Nov;155:387-394. doi: 10.1016/j.jpsychires.2022.09.016. Epub 2022 Sep 21.PMID: 36182768
  6. Livne O, Shmulewitz D, Lev-Ran S, Hasin DS. DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. Drug Alcohol Depend. 2019 Feb 1;195:170-177. doi: 10.1016/j.drugalcdep.2018.09.005. Epub 2018 Oct 22.PMID: 30361043
  7. Shmulewitz D, Budney AJ, Borodovsky JT, Bujno JM, Walsh CA, Struble CA, Livne O, Habib MI, Aharonovich E, Hasin DS. Dimensionality and differential functioning of DSM-5 cannabis use disorder criteria in an online sample of adults with frequent cannabis use.J Psychiatr Res. 2023 Jul;163:211-221. doi: 10.1016/j.jpsychires.2023.05.048. Epub 2023 May 16.PMID: 37224773

For a complete list of publications, please visit PubMed.gov